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Sleep apnea is among the most common chronic diseases of 
adults. Despite differences in methodology and disease defini-
tion, the prevalence of sleep apnea is consistently high across 
different cultures and populations. In a representative U.S. adult 
population sample from the state of Wisconsin, the prevalence 
of sleep apnea was estimated to be 9% of women and 24% of 
men aged 30-60 years,1 with even higher prevalence reported in 
the elderly. A high prevalence of sleep apnea has been reported 
in studies from around the world.2-5 By the 1980s, an associa-
tion of severe sleep apnea with mortality and cardiovascular 
disease was recognized. Over the subsequent two decades, a 
large body of observational research from community-based 
epidemiologic studies has established an association of sleep 
apnea with increased incidence of coronary heart disease, 
stroke, heart failure, and mortality after adjusting for established 
cardiovascular disease risk factors.6-11 Both human and animal 
physiologic studies have identified mechanisms whereby sleep 
apnea might cause cardiovascular morbidity and mortality, in-
cluding increased sympathetic nervous system activity, hypoxic 
and oxidative stress, systemic inflammation, impaired glucose 
handling, and mechanical factors increasing cardiac filling and 
ventricular transmural pressure.12,13 These findings provide bio-
logical plausibility to a causal association of sleep apnea with 
cardiovascular disease. It is important to note that, in contrast 
to patients seeking treatment in sleep disorders centers, as many 
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as half of individuals with moderate to severe sleep apnea in the 
general population do not report excessive sleepiness,14 and this 
is also true of samples of consecutive patients with established 
cardiovascular disease or heart failure. Should a causal associa-
tion exist between sleep apnea and cardiovascular disease, this 
would provide a strong rationale for treatment of sleep apnea 
even in the absence of daytime sleepiness.
To date, however, the ability of sleep apnea treatment to re-
duce cardiovascular morbidity and mortality has not been dem-
onstrated. Several observational studies comparing obstructive 
sleep apnea (OSA) patients treated with continuous positive air-
way pressure (CPAP) versus those not treated have found ele-
vated cardiovascular risk only in those with untreated OSA15-18; 
however, lack of treatment in these studies was self-selected 
based on refusal of or non-adherence to therapy, raising the pos-
sibility that increased cardiovascular risk was related to other 
factors associated with poor adherence to prescribed medical 
therapy. Multiple small, single-center randomized clinical trials 
evaluating intermediate physiologic endpoints have pointed to 
beneficial effects of treatment with CPAP on blood pressure, 
glucose tolerance or insulin resistance, subclinical measures of 
atherosclerosis, and left ventricular ejection fraction. A number 
of negative trials have also been reported and the possibility 
of positive publication bias further dampens enthusiasm for 
studies of this type to inform clinical practice. Moreover, even 
if the effect of CPAP is correctly estimated by these studies, 
caution must be exercised in extrapolating from these interme-
diate endpoint studies to clinical outcomes of interest. In this 
regard, the Canadian Positive Airway Pressure (CANPAP) Trial 
is particularly instructive. After small trials indicated that CPAP 
treatment of Cheyne-Stokes respiration in chronic heart failure 
resulted in dramatic improvements in left ventricular ejection 
fraction, the CANPAP study was conducted as a multicenter, 
randomized clinical trial to establish the benefits of this therapy 
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on transplant-free survival. Although an improvement in ejec-
tion fraction was observed, there was no improvement in trans-
plant-free survival and a trend toward increased early mortality 
in the CPAP-treated arm.19
Such considerations underscore the importance of well-
designed, multicenter, randomized clinical trials (RCTs) to 
evaluate the impact of sleep apnea treatment on cardiovascular 
morbidity and mortality. To date, few such studies have been 
undertaken. Almost two decades after the Wisconsin Sleep Co-
hort Study opened the eyes of the medical community to the 
high prevalence of sleep apnea, it is difficult to attribute the 
paucity of sleep apnea randomized clinical trials to the rela-
tive youth of the field of sleep medicine. The difficulty in con-
ducting such clinical trials should not be minimized, however. 
Cardiovascular clinical trials require large numbers of patients 
treated for a period of years in order to accrue a sufficient num-
ber of disease endpoints for meaningful analysis, necessitating 
coordination of data collection across multiple sites and requir-
ing substantial expertise and resources. In addition to the issues 
of regulatory compliance, harmonization of study procedures, 
subject recruitment, and secular changes in therapy that exist 
for any clinical trial, treatment trials for sleep apnea pose sev-
eral unique challenges.
First, there is a lack of standardization in the approach to 
characterizing baseline presence and severity of sleep apnea, 
with regard to both the parameters measured and the definition 
of sleep apnea. While diagnosis of sleep apnea has been tradi-
tionally based on polysomnography, this technique is expen-
sive and requires the availability of specialized facilities, both 
of which would hinder the conduct of large, multicenter inter-
national randomized clinical trials. Moreover, limited channel, 
home-based sleep apnea testing, typically measuring airflow, 
respiratory effort, and pulse oximetry, is now widely used in 
the clinical diagnosis of sleep apnea in the U.S. and throughout 
the world. While there is not a consensus regarding the param-
eters needed for adequate and consistent characterization of 
sleep apnea for inclusion of subjects in clinical trials, the use 
of simple portable monitoring devices may offer an affordable 
approach to large-scale screening such as would be required for 
international randomized clinical trials. Indeed, while it may be 
important to discriminate central from obstructive sleep apnea 
in the setting of patients with chronic heart failure20 or stroke, 
simple oximetry might be a sufficient screening tool in settings 
where discrimination of central from obstructive sleep apnea is 
not needed.
Another challenge in sleep apnea clinical trials relates to the 
use of a placebo treatment. While there is uncertainty regard-
ing the role of sleep apnea treatment in modifying long-term 
cardiovascular risk, there is consensus that sleep apnea treat-
ment improves symptoms of sleep apnea, in particular exces-
sive sleepiness. A threshold of symptoms below which it is 
ethical to withhold effective symptomatic therapy needs to be 
established, although potential biases introduced by exclud-
ing highly symptomatic patients must be considered. Beyond 
the ethics of placebo use, there is the question of which non-
therapeutic comparator is appropriate. Short-term randomized 
trials investigating neurocognitive function or intermediate car-
diometabolic endpoints have utilized various comparators, in-
cluding sham CPAP, subtherapeutic CPAP, placebo pills, nasal 
dilator strips, or a non-treatment control group without placebo. 
While sham devices have been validated as a placebo for CPAP, 
both patients and providers may be less willing to participate in 
a long duration clinical trial when the comparator is perceived 
as burdensome. Sham CPAP resulted in somewhat higher drop-
out rates over a 6-month trial,21 a problem that would likely 
increase in longer-term studies. Moreover, it is unclear whether 
they might themselves have an adverse impact on sleep quality 
and thus potentially bias results. At present, there is not consen-
sus on the ideal comparator in sleep apnea clinical trials.
Adherence to therapy over a period of years, as is needed 
in studies of cardiovascular morbidity and mortality, is a chal-
lenge in clinical trials generally. Adherence may be particularly 
difficult to achieve in sleep apnea cardiovascular trials, as pa-
tients with few or no sleep apnea symptoms are generally less 
tolerant of CPAP than are symptomatic sleep apnea patients. 
The relative improvement in study efficiency by utilizing run-in 
periods to identify early non-adherers is unclear. Short-term tri-
als have often utilized intensive participant contact to enhance 
CPAP adherence; however, trials that more closely approximate 
the actual practice of sleep medicine are more practical and bet-
ter suited to inform clinical decision-making. While an arbi-
trary threshold of at least four hours per night is often used to 
identify adequate CPAP adherence, the relation of duration of 
CPAP use to improved quality of life or cardiovascular benefit 
is uncertain. As contemporary CPAP devices provide accurate 
adherence data, there is an opportunity to embed studies of ad-
herence predictors within the framework of large randomized 
clinical trials and to carefully assess the relation of adherence 
to clinical outcomes.
Despite these challenges, the past several years have seen 
an increasing number of randomized clinical trials of sleep ap-
nea treatment. We have conducted a search of major worldwide 
clinical trials registry databases, including all registries con-
tributing data to the World Health Organization Clinical Trials 
Registry Platform, and included all trials submitted to the reg-
istry as of November 2012. The search was designed to return 
all studies including the key words “sleep apnea” plus any of 
the following terms: cardiovascular, cerebrovascular, stroke, 
or vascular. These studies were then individually reviewed to 
identify those that were randomized trials with a planned en-
rollment of ≥ 50 subjects, an intervention targeting sleep apnea, 
and a cardiovascular disease outcome. (Although early studies, 
including the CANPAP trial, may not have been registered, the 
International Committee of Medical Journal Editors guidelines 
require that all clinical trials beginning after 2005 be prospec-
tively registered in order to be considered for publication, and 
it is therefore unlikely that any currently active, large clinical 
trials would be unregistered.) This search identified 39 random-
ized clinical trials of sleep apnea treatment initiated after 2000 
with a target enrollment of at least 50 subjects and endpoints 
of blood pressure, cardiac function, functional status following 
stroke, or composite cardiovascular disease endpoints. These 
include 13 completed trials comprising 2,859 subjects (Table 1) 
and 27 on-going trials with a planned enrollment of 11,236 sub-
jects (Tables 2 and 3). This search identified multiple additional 
ongoing randomized trials assessing the impact of OSA therapy 
on biomarkers of cardiovascular risk, such as measures of oxi-
dative stress, endothelial function, or metabolic syndrome. The 
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majority of the trials with disease outcomes (17 of the 27 active 
studies) have blood pressure as the main outcome (Table 2). 
Because blood pressure is a continuous measure and changes 
can be detected over a relatively short period of time, such stud-
ies can generally be completed in less time, with fewer subjects 
and at lower cost than would be required for studies of dis-
crete disease endpoints such as myocardial infarction or stroke. 
In contrast to the average sample size of approximately 200 
subjects in completed cardiovascular sleep apnea studies, early 
studies demonstrating that statin therapy compared to placebo 
reduced the risk of incident or recurrent coronary events en-
rolled over 4,000 subjects31; to demonstrate a reduction in mor-
tality with statins, over 9,000 subjects were enrolled.32 Similar 
sample sizes may be needed to clearly demonstrate cardiovas-
cular risk reduction following sleep apnea treatment.
While samples of this magnitude have not yet been enrolled 
in sleep apnea cardiovascular trials, several recently complet-
ed studies have begun to raise the bar. The Spanish Sleep and 
Breathing Network, started in the mid-1990s, has been very 
active in conducting clinical trials based on the approach of 
a central committee that identifies relevant clinical questions, 
establishes funding streams, and selects participating centers 
for each project, providing technical support and guidance to 
researchers and pre-submission review of manuscripts. This 
network has recently published a randomized clinical trial as-
sessing a composite incident cardiovascular disease and hyper-
tension endpoint in 723 non-sleepy patients with sleep apnea, 
randomized to treatment with CPAP versus conservative ther-
apy for a median of 4.0 years.23 Reflecting both the relatively 
low power of even such an ambitious study and the potential 
importance of treatment adherence, the 17% reduction in risk 
observed in the CPAP-treated group was not statistically sig-
nificant, although a subgroup analysis suggested a significant 
benefit in CPAP-adherent (≥ 4 h/night) subjects. The Oxford 
group recently reported results of the Multicentre OSA Inter-
ventional Cardiovascular Trial (MOSAIC), which investigated 
the effects of CPAP on cardiovascular risk score, sleepiness 
and quality of life in 391 minimally symptomatic patients.29 
After 6 months of follow-up, the CPAP-treated group had a 
significant reduction in daytime sleepiness and self-assessed 
health status, but no improvement in cardiovascular risk score. 
Two large multicenter studies of adaptive pressure-support ser-
voventilation treatment of sleep apnea in patients with heart 
failure with reduced ejection fraction are currently in progress. 
Both the North America-based Adaptive Servoventilation for 
Treatment of OSA and CSA in Heart Failure (ADVENT-HF) 
study, enrolling heart failure patients with central sleep apnea 
or non-sleepy OSA, and the Europe-based Treatment of Pre-
dominant Central Sleep Apnoea by Adaptive Servo Ventilation 
in Patients With Heart Failure (SERVE-HF) study, enrolling 
heart failure patients with predominant central sleep apnea, 
will evaluate the impact of treatment on the clinically impor-
tant outcomes of mortality and cardiovascular hospitalization. 
The largest ongoing RCT, the Sleep Apnea Cardiovascular 
Table 1—Registered randomized clinical trials of sleep apnea treatment and cardiovascular endpoints (completed studies)
Clinical Trial 
Registry Number
Country of 
Performance Target Sample Intervention Primary Outcome
Start 
Date
Number of 
Subjects Reference
NCT00404807 Spain OSA, HF CPAP vs. CT LVEF 2004 73 22
NCT00127348 Spain Non-sleepy OSA CPAP vs. CT Composite 2005 723 23
NCT00202501 Spain OSA, recent stroke CPAP vs. CT Functional status 2005 140 24
NCT00459914 Spain OSA, refractory 
HTN
CPAP vs. CT 24-h ABPM 2005 75 25
NCT00202527 Spain OSA, HTN CPAP vs. Sham 24-h ABPM 2005 340 26
NCT00409487 France OSA, HTN CPAP vs. Valsartan 24-h ABPM 2006 60 27
NCT00701038 USA OSA, acute 
decompensated HF
CPAP vs. CT LVEF 2006 46 28
ISRCTN 34164388 United 
Kingdom
Non-sleepy OSA CPAP vs. CT Composite vascular 
risk score
2006 391 29
NCT00221065 Canada OSA, recent stroke CPAP vs. CT Functional status 2008 44 30
NCT00821210 China OSA, recent MI CPAP vs. Sham LVEF 2008 120 pending
NCT00984308 USA Stroke or TIA, HTN Diagnostic and 
CPAP treatment 
strategy versus CT 
24-h ABPM 2008 319 pending
NCT00616265 Spain OSA, resistant HTN CPAP vs. CT 24-h ABPM 2008 210 pending
NCT01086800 USA OSA, high CHD risk CPAP vs. O2 vs. CT 24-h ABPM 2010 318 pending
ABPM, ambulatory blood pressure monitoring; ACS, acute coronary syndrome; ADHF, acute decompensated heart failure; AF, atrial fibrillation; ASV, adaptive 
servoventilation; CHD, coronary heart disease; CPAP, continuous positive airway pressure; CSA, central sleep apnea; CT, conservative therapy; CV, 
cardiovascular; HF, heart failure; HTN, hypertension; LVEF, left ventricular ejection fraction; MAD, mandibular advancement device; MI, myocardial infarction; 
OSA, obstructive sleep apnea; TIA, transient ischemic attack.
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Endpoints (SAVE) study, has recruited over 2,000 of a planned 
2,500 patients with minimally symptomatic OSA and ischemic 
heart disease or cerebrovascular disease to study the impact of 
CPAP therapy on combined vascular events and mortality. This 
study has partnered with existing sleep clinical trials networks 
and with non-sleep clinical trialists who have experience in 
running large clinical trials in other fields of medicine. Reflect-
ing a cautious interest in the area of sleep apnea cardiovascu-
lar trials, the US National Institutes of Health have recently 
funded three planning grants, the Heart Biomarker Evaluation 
in Apnea Treatment (HeartBEAT, NCT01086800), Best Apnea 
Interventions in Research (BestAIR, NCT01261390), and the 
Sleep Apnea in TIA/Stroke (SleepTight, NCT01446913) stud-
ies to evaluate design approaches for a large scale clinical trial 
of CPAP for cardiovascular risk reduction, including effective-
ness of various recruitment strategies, methods for optimizing 
adherence, use of control treatments, intermediate endpoints 
most responsive to intervention, and the use of oxygen as an 
alternative to CPAP.
Even as these important trials are ongoing, some argue that 
clinical trials of sleep apnea treatment to prevent cardiovascu-
lar disease are unethical and that all patients with OSA should 
be treated to prevent cardiovascular complications. While there 
should be little debate that treatment is appropriate to reduce 
the symptoms of daytime sleepiness and nocturnal sleep dis-
ruption that often accompany sleep apnea, we believe that there 
is uncertainty with respect to the cardiovascular benefits of 
treatment of sleep apnea. Conversely, large-scale sleep apnea 
cardiovascular trials might be considered premature, as epide-
miologic studies show inconsistent associations of sleep apnea 
with cardiovascular risk across age and gender groups, while 
biomarkers identifying subsets of sleep apnea patients with in-
creased cardiovascular risk are lacking. Although there remain 
important questions to be addressed with observational studies, 
whose answers may inform the design of future clinical trials, 
the data supporting an association of sleep apnea with cardio-
vascular risk are sufficiently compelling, and the magnitude of 
the potential public health risk sufficiently great, that it is time 
to complete the inferential loop by demonstrating that effective 
treatment of sleep apnea will prevent cardiovascular morbidity 
and mortality.
To further this aim, an international collaboration of inves-
tigators, loosely modeled on the Spanish Sleep and Breathing 
Network, has been established. This International Collabora-
tion of Sleep Apnea Cardiovascular Trialists (INCOSACT) has 
the express goal of fostering international multicenter random-
ized clinical trials of sleep apnea treatment, with a particular 
focus on studies to reduce sleep apnea-related cardiovascular 
risk. The consortium aims to promote new research ideas and 
help researchers obtain funding by fostering academic-indus-
try partnerships and providing a credible framework to support 
the conduct of clinical trials. It will facilitate the sharing of ex-
pertise and, where appropriate, the standardization of method-
ology for diagnosis, treatment and monitoring of participants, 
and will help investigators negotiate the complex regulatory 
landscape that confronts international clinical trials. INCO-
SACT membership includes senior and junior investigators 
actively involved in the conduct of Phase 3 sleep apnea car-
Table 2—Registered randomized clinical trials of sleep apnea treatment and blood pressure endpoints (ongoing studies)
Clinical Trial 
Registry Number
Country of 
Performance
Target
Sample Intervention
Primary
Outcome
Start
Date
Number of 
Subjects (planned)
NCT00300872 China OSA CPAP vs. Sham BP 2005 140
NCT00300599 China OSA CPAP vs. Placebo BP 2006 100
ACTRN12607000289415 Australia OSA CPAP vs. MAD 24-h ABPM 2007 108
NCT00701428 Sweden OSA CPAP vs. CT 24-h ABPM 2008 90
NCT00801671 Russia OSA, HTN CPAP vs. Sham 24-h ABPM 2008 50
NCT00929175 Brazil OSA, resistant HTN CPAP vs. CT 24-h ABPM 2008 60
NCT00812695 Brazil OSA, resistant HTN CPAP vs. CT 24-h ABPM 2008 50
NCT00863135 Spain OSA, resistant HTN CPAP vs. CT 24-h ABPM 2008 70
NCT00746902 France OSA, resistant HTN CPAP vs. Sham 24-h ABPM 2008 130
NCT00881985 China OSA, resistant HTN CPAP vs. CT BP 2009 64
NCT01138865 India OSA CPAP vs. Sham BP 2009 90
NCT01226641 France OSA CPAP ± telemedicine BP 2009 220
NCT01090297 France OSA CPAP vs. Auto-CPAP 24-h ABPM 2010 322
NCT01461473 USA OSA CPAP vs. MAD Nocturnal MAP 2010 238
NCT01261390 USA OSA CPAP vs. Sham BP 2011 180
NCT01508754 Brasil Resistant SH / OSA CPAP vs. CT 24-h ABPM 2011 200 
NCT01505959 France OSA and high CV risk CPAP ± telemonitoring BP 2012 936 
Abbreviations: see Table 1.
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diovascular clinical trials (or Phase 2 trials expressly designed 
to test feasibility issues relevant to Phase 3 studies) as well 
as cardiovascular clinical trialists, and has representation from 
multiple continents and regions. An Executive Committee, 
whose members will rotate every 2-3 years, holds quarterly 
meetings by phone or video conference and annual meetings 
at an international sleep or respiratory conference. The INCO-
SACT secretariat is presently hosted by the American Sleep 
Medicine Foundation. An INCOSACT website is being de-
veloped (www.incosact.org) and will ultimately contain both 
public information regarding international sleep apnea clinical 
trials and a secure location for communication and document 
sharing among INCOSACT members. While the focus will be 
on large randomized clinical trials, the consortium will encour-
age and support the conduct of meta-analyses of data collected 
in smaller clinical trials and would welcome ideas for collabo-
ration on mechanistic research trials that could be embedded 
as sub-studies within larger research frameworks, facilitating 
basic research including genetic and biomarker assessments 
that might otherwise be prohibitively expensive. By promot-
ing large scale clinical research, INCOSACT hopes to assist 
investigators to answer some of the key remaining questions in 
cardiovascular sleep research.
ABBREVIATIONS
ABPM, ambulatory blood pressure monitoring
ACS, acute coronary syndrome
ADHF, acute decompensated heart failure
AF, atrial fibrillation
ASV, adaptive servoventilation
CHD, coronary heart disease
CPAP, continuous positive airway pressure
CSA, central sleep apnea
CT, conservative therapy
CV, cardiovascular
HF, heart failure
HTN, hypertension
INCOSACT, International Collaboration of Sleep Apnea 
Cardiovascular Trialists
LVEF, left ventricular ejection fraction
MAD, mandibular advancement device
MI, myocardial infarction
OSA, obstructive sleep apnea
RCT, randomized clinical trial
TIA, transient ischemic attack
DISCLOSURE STATEMENT
This was not an industry supported study. Dr. Gottlieb 
has served as a consultant to ResMed Corporation. Dr. Hee-
ley and Dr. McEvoy have received research support for the 
SAVE Trial from Philips Respironics, ResMed Inc., and Fish-
er and Paykel Healthcare. Dr. Redline has received research 
support from Philips Respironics, ResMed Foundation, and 
ResMed Inc.
Table 3—Registered randomized clinical trials of sleep apnea treatment and cardiac endpoints (ongoing studies)
Clinical Trial 
Registry Number
Country of 
Performance Target Sample Intervention Primary Outcome
Start 
Date
Number of 
Subjects 
(planned)
NCT00519597
(RICCADSA)
Sweden
(RICCADSA)
OSA, CHD CPAP vs. CT Composite
(CV mortality, stroke, MI, or 
revascularization)
2005 510
NCT00765713 Spain OSA, HF, ICD CPAP vs. CT Appropriate defibrillator discharges 2008 224
NCT00679549 USA OSA, ADHF CPAP vs. CT Change in LVEF 2008 170
NCT00733343
ISRCTN19572887
(SERVE-HF)
Multinational CSA, HF ASV vs. CT Composite
(mortality or HF hospitalization)
2008 1,260
NCT00738179
ACTR 12608000409370
(SAVE)
Multinational Stable CV disease 
or stroke
CPAP vs. CT Composite
(CV death, MI, stroke, or 
hospitalization for HF, TIA, or ACS)
2008 2,500
NCT00263757 USA OSA or CSA, recent 
cardioversion for AF
ASV vs. CT AF recurrence 2009 200
NCT01164592
(SERVE-HF substudy)
Germany CSA, HF ASV vs. CT LVEF 2010 300
NCT01128816
ISRCTN67500535
(ADVENT-HF)
Multinational OSA or CSA, HF SV vs. CT Composite
(death or CV hospitalization)
2010 860
NCT01335087
(ISAACC)
Spain OSA, ACS CPAP vs. CT Composite
(CV death, MI, stroke, or 
hospitalization for HF, TIA, or ACS)
2011 1,864
NCT01561677 Canada Stroke CPAP vs. CT Functional independence 2011 300
Abbreviations: see Table 1.
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